Clinical trial: Adjuvant tamoxifen may reduce recurrence risk for patients with 'good-risk' DCIS who forgo radiation
For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according ...
Dec 12, 2024
0
9









